Dalbavancin-d6

Dalbavancin-d6 is a deuterated derivative of Dalbavancin, a lipoglycopeptide antibiotic used to treat skin and soft tissue infections caused by Gram-positive bacteria. The deuterated compound is used in pharmacokinetic and pharmacodynamic studies to understand the drug's metabolic pathways and its interactions with other medications. Dalbavancin-d6 is administered intravenously, and its effects are long-lasting due to its extended half-life of approximately 200 hours. The drug works by inhibiting bacterial cell wall synthesis, leading to bacterial death. It is highly effective against strains of Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). In terms of chemical information, Dalbavancin-d6 is a lipoglycopeptide consisting of two distinct peptide units with a lipid side chain attached to the N-terminus. The deuterium substitution in the compound does not affect its mechanism of action or pharmacokinetics. Dalbavancin-d6 should only be used under the guidance of a healthcare professional due to its potential side effects, including nausea, diarrhea, headache, and allergic reactions. It is important to note that the use of antibiotics, including Dalbavancin-d6, can lead to the development of antibiotic resistance if not used appropriately.